Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

GlobeNewswire10/09 03:15

Cingulate Shares Are Trading Lower. The Company Announced It Commenced Its Final FDA-required Study, Which Is a Food Effect Study, for CTx-1301 for the Treatment of Attention Deficit Hyperactivity Disorder.

Benzinga09/13 00:20

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

GlobeNewswire09/12 20:30

12 Health Care Stocks Moving In Monday's Intraday Session

Benzinga09/03 00:30

Cingulate to Participate in Benzinga All Live Access Event

newsfilter.io08/28 04:30

How Is The Market Feeling About Cingulate?

Benzinga08/27 22:45